| BioClinica to Participate in Upcoming Leading Healthcare Conferences (Business Wire) NEWTOWN, Pa.----BioClinicaâ„¢, Inc., , a global provider of clinical trial management services, today announced it will exhibit and present at several key, upcoming healthcare conferences scheduled during June and July. us.rd.yahoo.com |
Biotech Sector Feeling the Winds of Change: Three ETFs Offering Exposure Tom Lydon submits: The biotechnology sector is about to see some major shifts as patents expire and M&A activity gathers steam. ETFs are one of the best ways to get exposure to this dynamic and unpredictable sector. Speculating on biotech mergers and acquisitions is about as solid a strategy as playing roulette, says John Jannarone for The Wall Street Journal. In other words, the house always wins.Complete Story » seekingalpha.com |
LabCorp Establishes Global Clinical Trials Collaboration with Clearstone Central Labs (Business Wire) BURLINGTON, N.C.----Laboratory Corporation of America® Holdings announced today a collaboration between Esoterix Clinical Trials Services, a division of LabCorp, and Clearstone Central Laboratories, a global central laboratory specializing in drug development and pharmaceutical services. us.rd.yahoo.com |
Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants [PR Newswire] - Spherix Incorporated , an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it has entered into agreements to sell $5.25 million of shares of its Series B Convertible Preferred Stock and warrants to purchase shares of its common stock in a registered offering to institutional investors. Â Each share of Series B Convertible Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 800 shares of common stock at a conversion price of $1.25 per share of common stock for a total of approximately 4.2 million common shares. us.rd.yahoo.com |
Trius Announces Issuance of Key U.S. Patent for Torezolid Phosphate [PR Newswire] - Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office . The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate , currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections . us.rd.yahoo.com |